Published in J Anal Toxicol on October 01, 2006
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem (2007) 1.32
Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther (2012) 1.04
Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. Ther Drug Monit (2010) 0.95
Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol (2009) 0.94
Drug testing for newborn exposure to illicit substances in pregnancy: pitfalls and pearls. Int J Pediatr (2011) 0.80
Pharmacodynamic evaluation of the cardiovascular effects after the coadministration of cocaine and ethanol. Drug Metab Dispos (2008) 0.80
Simultaneous determination of L-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: application in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.78
Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. Bioanalysis (2015) 0.77
Phenytoin toxicity from cocaine adulteration. West J Emerg Med (2014) 0.75
Norcocaine and cocaethylene distribution patterns in hair samples from light, moderate, and heavy cocaine users. Drug Test Anal (2015) 0.75
Amphetamines analysis in wastewaters - method performance of solid phase extraction - higher performance liquid chromatography mass spectrometry techniques (SPE-HPLC MS/MS). EXCLI J (2011) 0.75
Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med (2004) 4.55
Why should addiction medicine be an attractive field for young physicians? Addiction (2008) 3.52
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend (2003) 2.68
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers. Addiction (2012) 2.20
Cannabis effects on driving skills. Clin Chem (2012) 2.04
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Guidelines for research on drugged driving. Addiction (2008) 1.87
Methadone maintenance and breastfeeding in the neonatal period. Pediatrics (2008) 1.86
The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav (2002) 1.74
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem (2003) 1.66
Cocaine craving and use during daily life. Psychopharmacology (Berl) (2009) 1.62
Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry (2012) 1.62
Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A (2010) 1.53
Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry (2005) 1.48
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem (2003) 1.48
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend (2009) 1.42
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend (2009) 1.40
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Is THC-COOH a useful determinant for passive inhalation in oral fluid THC testing? J Anal Toxicol (2012) 1.39
Questions on conflict of interest. Am J Psychiatry (2010) 1.38
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom (2003) 1.31
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res (2003) 1.28
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics (2010) 1.26
Cognitive measures in long-term cannabis users. J Clin Pharmacol (2002) 1.23
Caffeine content of energy drinks, carbonated sodas, and other beverages. J Anal Toxicol (2006) 1.23
Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem (2002) 1.23
Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol (2010) 1.22
Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol (2004) 1.21
Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr (2010) 1.21
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (2009) 1.21
Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend (2005) 1.20
Prenatal and postnatal cocaine exposure predict teen cocaine use. Neurotoxicol Teratol (2010) 1.19
Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol (2002) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Caffeine content of specialty coffees. J Anal Toxicol (2003) 1.16
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit (2004) 1.16
Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol (2009) 1.16
Oral fluid as a diagnostic tool. Clin Chem Lab Med (2004) 1.15
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 1.15
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend (2012) 1.14
Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact (2007) 1.12
Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol (2003) 1.11
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol (2008) 1.10
Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit (2009) 1.10
Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol (2009) 1.09
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol (2005) 1.08
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit (2006) 1.07
A mechanism for the inhibition of neural progenitor cell proliferation by cocaine. PLoS Med (2008) 1.07
State of the art treatments for cannabis dependence. Psychiatr Clin North Am (2012) 1.07
The second-oldest state psychiatric hospital in the United States. Am J Psychiatry (2014) 1.06
Calorie restriction increases cigarette use in adult smokers. Psychopharmacology (Berl) (2004) 1.06